Claims for Patent: 11,052,064

Summary for Patent: 11,052,064

Title:	Compositions, methods and systems for the treatment of cutaneous disorders
Abstract:	Devices, systems, methods, and kits for treating cutaneous diseases, such as warts, with a cantharidin formulation are generally described. The cantharidin formulations, described herein, may have many advantages over traditional cantharidin formulations, including removal of highly volatile and corrosive solvents, improved safety, and improved compatibility with common plastics for ease of delivery. The devices, systems, methods, and kits can be used for the precise application of the cantharidin formulation for the treatment of cutaneous diseases and other topical indications. Treatment of cutaneous diseases with cantharidin, using the devices, systems, methods, and/or kits may have many advantages over traditional therapies, including high single application efficacy, lack of scaring, and a mild pain profile.
Inventor(s):	Matthew Gene Davidson
Assignee:	Verrica Pharmaceuticals Inc
Application Number:	US14/913,335
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 11,052,064
Patent Claims:	1. A system for delivering a cantharidin formulation to a subject, comprising: a reservoir comprising a cavity containing a cantharidin formulation, wherein the cantharidin formulation comprises at least 0.001% (w/v) of cantharidin, acetone, ethanol, a gelling agent, and a film-forming agent; wherein the gelling agent is hydroxypropyl cellulose; the film-forming agent is nitrocellulose; and the cantharidin formulation is free of diethyl ether; and an applicator unit in fluid communication with the reservoir, wherein the reservoir holds a volume less than or equal to 10 milliliters (mL) of the cantharidin formulation. 2. The system of claim 1, wherein the cantharidin formulation comprises at least 0.5% (w/v) cantharidin. 3. The system of claim 1, wherein the cantharidin formulation comprises between 0.1% and 10% (w/v) of the film-forming agent. 4. The system of claim 1, wherein the applicator unit comprises a puncturable barrier on one end and a cap engaging the applicator unit to cover the puncturable barrier. 5. The system of claim 4, wherein the cap is a screw-on or snap-on cap. 6. The system of claim 4, wherein the cap is transparent. 7. The system of claim 4, wherein the cap comprises a puncture apparatus for punching through the barrier prior to use of the applicator unit. 8. The system of claim 1, wherein the opening of the applicator unit comprises a tip having a diameter less than or equal to 5 mm. 9. The system of claim 1, wherein the system provides for controlled delivery of the cantharidin formulation to the subject. 10. The system of claim 1, wherein the cantharidin formulation further comprises a flavorant that induces a bitter taste to prevent or deter licking and/or ingestion of the formulation by a subject. 11. The system of claim 10, wherein the flavorant is selected from the group consisting of denatonium, amarogentin, gentiopicrin, sucrose octaacetate, quercetin, brucine, and quassin. 12. The system of claim 1, further comprising a colorant selected from the group consisting of D&C violet, isosulfan blue, methylene blue, methyl red, methyl orange, congo red, alizarin yellow, bromocresol green, and gentian violet. 13. The system of claim 1, wherein the cantharidin formulation further comprises one or more plasticizers. 14. The system of claim 13, wherein the one or more plasticizers comprise camphor and castor oil. 15. The system of claim 1, wherein the cantharidin formulation has a Reynolds number less than 1500 at 25° C. 16. The system of claim 1, wherein the cantharidin formulation has a viscosity of more than 5 centipoise and less than 100 centipoise. 17. The system of claim 1, wherein the cantharidin formulation comprises 55% (w/v) or more of acetone; and 30% (w/v) or more of ethanol. 18. The system of claim 1, wherein the cantharidin formulation further comprises a colorant that enables visible detection of the formulation by the subject. 19. The system of claim 1, wherein the cantharidin formulation comprises: ethanol in an amount up to 99% (w/v); acetone in an amount up to 99% (w/v); hydroxypropyl cellulose in an amount up to 10% (w/v); nitrocellulose in an amount up to 10% (w/v); castor oil in an amount up to 5% (w/v); camphor in an amount up to 5% (w/v); and cantharidin in amount from 0.001-7% (w/v). 20. The system of claim 19, wherein the cantharidin formulation further comprises: denatonium benzoate in an amount from 0.00001-1% (w/v); and gentian violet in an amount from 0.00001-1% (w/v). 21. A method for delivering a cantharidin formulation to a subject for treating a condition susceptible to treatment with the cantharidin formulation, comprising: providing an applicator device comprising a reservoir comprising the cantharidin formulation and an applicator unit comprising a channel in fluid communication with the reservoir; and delivering the cantharidin formulation from the reservoir through the channel to the subject, wherein the cantharidin formulation comprises at least 0.001% (w/v) of cantharidin, acetone, ethanol, a gelling agent, and a film-forming agent; wherein the gelling agent is hydroxypropyl cellulose; the film-forming agent is nitrocellulose; and the cantharidin formulation is free of diethyl ether. 22. The method of claim 21, wherein the cantharidin formulation comprises at least 0.5% (w/v) cantharidin. 23. The method of claim 21, wherein the cantharidin formulation comprises between 0.1% and 10% (w/v) of the film-forming agent. 24. The method of claim 21, wherein the subject is diagnosed with a skin disease. 25. The method of claim 24, wherein the skin disease is an epithelial wart, a Molluscum lesion, actinic keratosis, or seborrheic keratosis. 26. The method of claim 24, wherein the skin disease is a common wart, genital wart, or plantar wart. 27. The method of claim 24, wherein the skin disease is Molluscum contagiosum. 28. The method of claim 24, wherein the skin disease is caused by human papilloma virus (HPV). 29. The method of claim 21, wherein the delivering comprises delivering less than or equal to 10 milliliters (mL) of the cantharidin formulation. 30. The method of claim 21, wherein the cantharidin formulation is administered in a time period that is less than or equal to 30 seconds. 31. The method of claim 21, wherein the delivery of the cantharidin formulation is controlled delivery. 32. The method of claim 21, wherein the cantharidin formulation has a viscosity of more than 5 centipoise and less than 100 centipoise. 33. The method of claim 21, wherein the cantharidin formulation comprises 55% (w/v) or more of acetone; and 30% (w/v) or more of ethanol. 34. The method of claim 21, wherein the cantharidin formulation comprises: ethanol in an amount up to 99% (w/v); acetone in an amount up to 99% (w/v); hydroxypropyl cellulose in an amount up to 10% (w/v); nitrocellulose in an amount up to 10% (w/v); castor oil in an amount up to 5% (w/v); camphor in an amount up to 5% (w/v); and cantharidin in amount from 0.001-7% (w/v). 35. The method of claim 34, wherein the cantharidin formulation further comprises: denatonium benzoate in an amount from 0.00001-1% (w/v); and gentian violet in an amount from 0.00001-1% (w/v). 36. A kit for administering a cantharidin formulation to a subject, comprising: a plurality of separately packaged, individually removable, dosage units in liquid or gel form, wherein the dosage units are in a packaging unit, and wherein the dosage units each comprise the cantharidin formulation in an amount from 0.01 mL to 10 mL, wherein the cantharidin formulation comprises at least 0.001% (w/v) of cantharidin, acetone, ethanol, a gelling agent, and a film-forming agent; wherein the gelling agent is hydroxypropyl cellulose; the film-forming agent is nitrocellulose; and the cantharidin formulation is free of diethyl ether; the kit further comprising instructional material for administering the cantharidin formulation for treating a condition susceptible to treatment using the cantharidin formulation. 37. A formulation comprising: at least 0.001% (w/v) of cantharidin; acetone; ethanol; a film-forming agent, wherein the film-forming agent is nitrocellulose; and a gelling agent, wherein the gelling agent is hydroxypropyl cellulose; and the formulation is free of diethyl ether. 38. The formulation of claim 37, wherein the formulation has a Reynolds number less than 1500 at 25° C. 39. The formulation of claim 37, further comprising a flavorant selected from the group consisting of denatonium, amarogentin, gentiopicrin, sucrose octaacetate, quercetin, brucine, and quassin. 40. The formulation of claim 37, further comprising a colorant selected from the group consisting of D&C violet, isosulfan blue, methylene blue, methyl red, methyl orange, congo red, alizarin yellow, bromocresol green, and gentian violet. 41. The formulation of claim 37, further comprising one or more plasticizers. 42. The formulation of claim 41, wherein the one or more plasticizers comprise camphor and castor oil. 43. The formulation of claim 37, wherein the formulation has a viscosity of more than 5 centipoise and less than 100 centipoise. 44. The formulation of claim 37, wherein the formulation comprises 55% (w/v) or more of acetone; and 30% (w/v) or more of ethanol. 45. The formulation of claim 37, wherein the formulation further comprises a flavorant that induces a bitter taste to prevent or deter licking and/or ingestion of the formulation by a subject. 46. The formulation of claim 37, wherein the formulation further comprises a colorant that enables visible detection of the formulation by the subject. 47. The formulation of claim 37, comprising: ethanol in an amount up to 99% (w/v); acetone in an amount up to 99% (w/v); hydroxypropyl cellulose in an amount up to 10% (w/v); nitrocellulose in an amount up to 10% (w/v); castor oil in an amount up to 5% (w/v); camphor in an amount up to 5% (w/v); and cantharidin in amount from 0.001-7% (w/v). 48. The formulation of claim 47 further comprising: denatonium benzoate in an amount from 0.00001-1% (w/v); and gentian violet in an amount from 0.00001-1% (w/v).